The TRADE study: A Phase 2 Trial to Assess the ToleRability of Abemaciclib Dose Escalation in Patients with Early-Stage HR-positive and HER2-negative Breast Cancer (DF/HCC 23-355) (NCT06001762)

In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage high-risk hormone receptor positive breast cancer.

The names of the study drugs involved in this study are:

  • Abemaciclib (CDK4 and CDK6 inhibitor)
  • Tamoxifen (Selective estrogen receptor modulator)

Learn More

Principal Investigator(s)

Steve Lo, MD


Mary Miller, LPN at 203-358-8879 or [email protected]


Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.